WO2003082893A3 - Theraputic methods and uses of sapogenins and their derivatives - Google Patents

Theraputic methods and uses of sapogenins and their derivatives Download PDF

Info

Publication number
WO2003082893A3
WO2003082893A3 PCT/GB2003/001380 GB0301380W WO03082893A3 WO 2003082893 A3 WO2003082893 A3 WO 2003082893A3 GB 0301380 W GB0301380 W GB 0301380W WO 03082893 A3 WO03082893 A3 WO 03082893A3
Authority
WO
WIPO (PCT)
Prior art keywords
derivatives
sapogenins
cognitive
methods
theraputic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2003/001380
Other languages
French (fr)
Other versions
WO2003082893A2 (en
WO2003082893A8 (en
Inventor
Daryl Rees
Phil Gunning
Antonia Orsi
Zongqin Xia
Yaer Hu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phytopharm Ltd
Original Assignee
Phytopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ARP020101170A external-priority patent/AR033079A1/en
Priority to KR1020127008441A priority Critical patent/KR20120128596A/en
Priority to AU2003229877A priority patent/AU2003229877B8/en
Priority to JP2003580357A priority patent/JP4573157B2/en
Priority to BR0308788-3A priority patent/BR0308788A/en
Priority to HR20041009A priority patent/HRP20041009A2/en
Priority to EP03722713A priority patent/EP1490071B1/en
Application filed by Phytopharm Ltd filed Critical Phytopharm Ltd
Priority to KR1020047014567A priority patent/KR101130212B1/en
Priority to HK04110420.5A priority patent/HK1067546B/en
Priority to US10/507,000 priority patent/US20050130948A1/en
Priority to MXPA04009321A priority patent/MXPA04009321A/en
Priority to CN038071886A priority patent/CN1642558B/en
Priority to NZ535093A priority patent/NZ535093A/en
Priority to IL16416103A priority patent/IL164161A0/en
Priority to CA2477787A priority patent/CA2477787C/en
Priority to DE60326437T priority patent/DE60326437D1/en
Publication of WO2003082893A2 publication Critical patent/WO2003082893A2/en
Publication of WO2003082893A8 publication Critical patent/WO2003082893A8/en
Publication of WO2003082893A3 publication Critical patent/WO2003082893A3/en
Anticipated expiration legal-status Critical
Priority to NO20044468A priority patent/NO20044468L/en
Priority to AU2008207565A priority patent/AU2008207565A1/en
Priority to US13/085,225 priority patent/US20110190249A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Catalysts (AREA)

Abstract

The invention discloses therapeutic methods and uses of certain steroidal sapogenins, related compounds and derivatives thereof, in the treatment of non-cognitive neurodegeneration, non-cognitive neuromuscular degeneration, motor-sensory neurodegeneration or receptor dysfunction or loss in the absence of cognitive, neural and neuromuscular impairment.
PCT/GB2003/001380 2002-03-27 2003-03-27 Theraputic methods and uses of sapogenins and their derivatives Ceased WO2003082893A2 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
NZ535093A NZ535093A (en) 2002-03-27 2003-03-27 Therapeutic methods and uses of sapogenins and their derivatives
MXPA04009321A MXPA04009321A (en) 2002-03-27 2003-03-27 Theraputic methods and uses of sapogenins and their derivatives.
JP2003580357A JP4573157B2 (en) 2002-03-27 2003-03-27 Method of treatment and use of sapogenin and its derivatives
BR0308788-3A BR0308788A (en) 2002-03-27 2003-03-27 Therapeutic processes and uses of sapogenins and their derivatives
HR20041009A HRP20041009A2 (en) 2002-03-27 2003-03-27 Theraputic methods and uses of sapogenins and their derivatives
EP03722713A EP1490071B1 (en) 2002-03-27 2003-03-27 Therapeutic uses of sapogenins
AU2003229877A AU2003229877B8 (en) 2002-03-27 2003-03-27 Theraputic methods and uses of sapogenins and their derivatives
KR1020047014567A KR101130212B1 (en) 2002-03-27 2003-03-27 Theraputic methods and uses of SAPOGENIN and their derivatives
HK04110420.5A HK1067546B (en) 2002-03-27 2003-03-27 Therapeutic uses of sapogenins
US10/507,000 US20050130948A1 (en) 2002-03-27 2003-03-27 Therapeutic methods and uses of sapogenins and their derivatives
CN038071886A CN1642558B (en) 2002-03-27 2003-03-27 Uses of saponins and derivatives thereof
KR1020127008441A KR20120128596A (en) 2002-03-27 2003-03-27 Theraputic methods and uses of sapogenin and their derivatives
DE60326437T DE60326437D1 (en) 2002-03-27 2003-03-27 THERAPEUTIC USE OF SAPOGENINES
IL16416103A IL164161A0 (en) 2002-03-27 2003-03-27 Therapeutic methods and uses of sapogenins and their derivatives
CA2477787A CA2477787C (en) 2002-03-27 2003-03-27 Therapeutic methods and uses of sapogenins and their derivatives
NO20044468A NO20044468L (en) 2002-03-27 2004-10-20 Use of sapogenins and hence in the manufacture of drugs
AU2008207565A AU2008207565A1 (en) 2002-03-27 2008-08-27 Therapeutic methods and uses of sapogenins and their derivatives
US13/085,225 US20110190249A1 (en) 2002-03-27 2011-04-12 Therapeutic methods and uses of sapogenins and their derivatives

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
ARP020101170A AR033079A1 (en) 2001-03-28 2002-03-27 SAPOGENINE DERIVATIVES, SYNTHESIS AND USE, AND METHODS BASED ON USE
ARP020101170 2002-03-27
US36817802P 2002-03-28 2002-03-28
US60/368,178 2002-03-28
PCT/GB2002/001578 WO2002079221A2 (en) 2001-03-28 2002-03-28 Sapogenin derivatives, their synthesis and use
GBPCT/GB02/01578 2002-03-28

Publications (3)

Publication Number Publication Date
WO2003082893A2 WO2003082893A2 (en) 2003-10-09
WO2003082893A8 WO2003082893A8 (en) 2003-12-31
WO2003082893A3 true WO2003082893A3 (en) 2004-04-15

Family

ID=30001210

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/001380 Ceased WO2003082893A2 (en) 2002-03-27 2003-03-27 Theraputic methods and uses of sapogenins and their derivatives

Country Status (10)

Country Link
KR (1) KR20100093621A (en)
CN (1) CN1642558B (en)
AT (1) ATE424211T1 (en)
IL (1) IL164161A0 (en)
NZ (2) NZ547897A (en)
PE (1) PE20040306A1 (en)
PL (1) PL213697B1 (en)
RU (1) RU2332999C2 (en)
TW (1) TWI329016B (en)
WO (1) WO2003082893A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861788B2 (en) * 2003-06-03 2005-03-01 Motorola, Inc. Switchable display/mirror method and apparatus
FR2868700B1 (en) * 2004-04-09 2008-09-26 Michel Coisy USE OF DOPAMINE OR ITS BIOLOGICAL PRECURSORS AGAINST ALGONURODYSTRPHY.
GB0409567D0 (en) 2004-04-28 2004-06-02 Phytopharm Plc Chemical compounds
GB0424528D0 (en) * 2004-11-05 2004-12-08 Phytopharm Plc Chemical compounds
JP5166272B2 (en) 2005-10-28 2013-03-21 キム・スンヨウ An extract of a plant of the genus Yamaceae, and a composition for preventing or treating peripheral neuropathy containing the same
CA2750510A1 (en) 2009-01-24 2010-07-29 Phytopharm Plc Treatment of neurotrophic factor mediated disorders
RU2402325C1 (en) * 2009-02-02 2010-10-27 Государственное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Method of treating neurovascular complications of diabetes
JP2013543482A (en) * 2010-07-20 2013-12-05 ファイトファーム ピーエルシー Treatment of diseases induced by L-dopa, dopamine agonists and / or dopamine activators
FI2753632T3 (en) 2011-09-08 2023-08-02 Sage Therapeutics Inc Neuroactive steroids, compositions, and uses thereof
CU20110244A7 (en) * 2011-12-27 2013-08-29 Ct De Investigación Y Desarrollo De Medicamentos Cidem SPI-ESTEROID SYSTEMS WITH NEUROACTIVE AND ANTI-INFLAMMATORY EFFECTS
WO2013149580A1 (en) * 2012-04-03 2013-10-10 Chiming Che Timosaponin compounds
RS67266B1 (en) 2013-03-13 2025-10-31 Sage Therapeutics Inc Neuroactive steriods and methods of use thereof
CN103232520A (en) * 2013-05-13 2013-08-07 中国药科大学 Spirosteroid compounds and preparation method and medical application thereof
ES2970222T3 (en) 2014-06-18 2024-05-27 Sage Therapeutics Inc Oxysterols and procedures for their use
MA42409A (en) 2015-07-06 2018-05-16 Sage Therapeutics Inc OXYSTEROLS AND THEIR METHODS OF USE
FI3828194T3 (en) 2015-07-06 2025-07-17 Sage Therapeutics Inc Oxysterols and methods of use thereof
MX390271B (en) 2015-07-06 2025-03-20 Sage Therapeutics Inc Oxysterols and methods of use thereof
US20190330259A1 (en) 2016-04-01 2019-10-31 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
LT3481846T (en) 2016-07-07 2021-08-25 Sage Therapeutics, Inc. 11-substituted 24-hydroxysterols for use in the treatment of nmda related conditions
JP7149266B2 (en) 2016-09-30 2022-10-06 セージ セラピューティクス， インコーポレイテッド Methods as C7-Substituted Oxysterols and NMDA Modulators
MA46566A (en) 2016-10-18 2019-08-28 Sage Therapeutics Inc OXYSTEROLS AND THEIR METHODS OF USE
IL293231B2 (en) 2016-10-18 2025-10-01 Sage Therapeutics Inc Oxysterols and methods of using them
CN108264535A (en) * 2016-12-30 2018-07-10 中国科学院上海药物研究所 A kind of antidepressant compounds and its preparation method and application
RU2635485C1 (en) * 2017-03-21 2017-11-13 Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Method for optic nerve atrophy treatment after craniocerebral injury
CN109988218B (en) * 2017-12-29 2022-11-25 中国科学院上海药物研究所 Sarsasapogenin derivative and preparation method and application thereof
EP3572085A1 (en) 2018-05-25 2019-11-27 Neuro-Sys Synergestic combination composition comprising a steroidal saponin, a first polyphenolic compound and optionnaly a second polyphenolic compound
CN112457362B (en) * 2019-09-06 2023-09-19 上海青东生物科技有限公司 A halogenated tetracyclic triterpene derivative and its preparation and application
US12454547B2 (en) 2022-04-22 2025-10-28 Asteroid Therapeutics Steroidal compositions and methods of treating lipogenic cancers
CN118994294A (en) * 2024-08-08 2024-11-22 吉林农业大学 Separation and identification and application of novel steroid saponin in allium macrostemon

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0162330A1 (en) * 1984-04-30 1985-11-27 Roecar Holdings (Netherlands Antilles) N.V. Use of sterolins and spiroketalins in the production of medicaments for the treatment of psoriasis
US4680289A (en) * 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
JPH05246866A (en) * 1992-03-06 1993-09-24 Ruibosuteii Japan:Kk Agent for stimulating cerebral metabolism and for improving cerebral function
DE4303214A1 (en) * 1993-02-04 1994-08-11 Wolfgang Marks Treatment of diseases of viral, viroidal or oncogenic origin by steroid saponins or their aglycones
EP0659762A2 (en) * 1993-12-24 1995-06-28 Mitsubishi Chemical Corporation Sialic acid derivatives
JPH092957A (en) * 1995-06-22 1997-01-07 Mitsubishi Chem Corp Therapeutic and preventing agent for peripheral neuropathy
JPH092956A (en) * 1995-06-22 1997-01-07 Mitsubishi Chem Corp Therapeutic and preventing agent for neuropathy
WO1998002450A2 (en) * 1996-07-11 1998-01-22 Inflazyme Pharmaceuticals Ltd. 6,7-oxygenated steroids and uses related thereto
WO1999048507A2 (en) * 1998-03-26 1999-09-30 Phytopharm Plc Steroidal saponins for treating alzheimer's disease
EP1024146A1 (en) * 1997-09-26 2000-08-02 Institute of Radiation Medicine Academy of Military Medical Sciences of the Pla The use of steroid saponin compounds to prevent senility, and novel steroid saponin compounds
WO2001023406A1 (en) * 1999-09-29 2001-04-05 Phytopharm Plc 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia
WO2001023408A1 (en) * 1999-09-29 2001-04-05 Phytopharm Plc 5-hydroxysapogenin derivatives with anti-dementia activity
WO2001023407A1 (en) * 1999-09-29 2001-04-05 Phytopharm Plc Sapogenin derivatives and their use in the treatment of cognitive dysfunction
WO2001049703A2 (en) * 2000-01-06 2001-07-12 Phytopharm Plc Substituted sapogenins and their use
JP2002030096A (en) * 2000-07-11 2002-01-29 Kyorin Pharmaceut Co Ltd Neurite outgrowth regenerating agent and method for producing the same
WO2003077869A2 (en) * 2002-03-15 2003-09-25 Samaritan Pharmaceuticals, Inc Neuroprotective spirostenol pharmaceutical compositions

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0162330A1 (en) * 1984-04-30 1985-11-27 Roecar Holdings (Netherlands Antilles) N.V. Use of sterolins and spiroketalins in the production of medicaments for the treatment of psoriasis
US4680289A (en) * 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
JPH05246866A (en) * 1992-03-06 1993-09-24 Ruibosuteii Japan:Kk Agent for stimulating cerebral metabolism and for improving cerebral function
DE4303214A1 (en) * 1993-02-04 1994-08-11 Wolfgang Marks Treatment of diseases of viral, viroidal or oncogenic origin by steroid saponins or their aglycones
EP0659762A2 (en) * 1993-12-24 1995-06-28 Mitsubishi Chemical Corporation Sialic acid derivatives
JPH092957A (en) * 1995-06-22 1997-01-07 Mitsubishi Chem Corp Therapeutic and preventing agent for peripheral neuropathy
JPH092956A (en) * 1995-06-22 1997-01-07 Mitsubishi Chem Corp Therapeutic and preventing agent for neuropathy
WO1998002450A2 (en) * 1996-07-11 1998-01-22 Inflazyme Pharmaceuticals Ltd. 6,7-oxygenated steroids and uses related thereto
EP1024146A1 (en) * 1997-09-26 2000-08-02 Institute of Radiation Medicine Academy of Military Medical Sciences of the Pla The use of steroid saponin compounds to prevent senility, and novel steroid saponin compounds
WO1999048507A2 (en) * 1998-03-26 1999-09-30 Phytopharm Plc Steroidal saponins for treating alzheimer's disease
WO2001023406A1 (en) * 1999-09-29 2001-04-05 Phytopharm Plc 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia
WO2001023408A1 (en) * 1999-09-29 2001-04-05 Phytopharm Plc 5-hydroxysapogenin derivatives with anti-dementia activity
WO2001023407A1 (en) * 1999-09-29 2001-04-05 Phytopharm Plc Sapogenin derivatives and their use in the treatment of cognitive dysfunction
WO2001049703A2 (en) * 2000-01-06 2001-07-12 Phytopharm Plc Substituted sapogenins and their use
JP2002030096A (en) * 2000-07-11 2002-01-29 Kyorin Pharmaceut Co Ltd Neurite outgrowth regenerating agent and method for producing the same
WO2003077869A2 (en) * 2002-03-15 2003-09-25 Samaritan Pharmaceuticals, Inc Neuroprotective spirostenol pharmaceutical compositions

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199343, Derwent World Patents Index; Class B04, AN 1993-339641, XP002157713 *
INOUE K ET AL: "Cholestanol induces apoptosis of cerebellar neuronal cells.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. UNITED STATES 5 MAR 1999, vol. 256, no. 1, 5 March 1999 (1999-03-05), pages 198 - 203, XP001188107, ISSN: 0006-291X *
KYOUNG SOOK KIM, ET AL.: "Effects of cholestanol feeding on corneal dystrophy in mice.", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1085, 1991, pages 343 - 349, XP008027217 *
PATENT ABSTRACTS OF JAPAN vol. 1997, no. 05 30 May 1997 (1997-05-30) *
PATENT ABSTRACTS OF JAPAN vol. 2002, no. 05 3 May 2002 (2002-05-03) *
SUN, HUI ET AL: "Retinal stimulates ATP hydrolysis by purified and reconstituted ABCR, the photoreceptor-specific ATP-binding cassette transporter responsible for Stargardt disease", JOURNAL OF BIOLOGICAL CHEMISTRY (1999), 274(12), 8269-8281, XP001165795 *

Also Published As

Publication number Publication date
WO2003082893A2 (en) 2003-10-09
PL372941A1 (en) 2005-08-08
PE20040306A1 (en) 2004-05-29
RU2332999C2 (en) 2008-09-10
TW200400042A (en) 2004-01-01
PL213697B1 (en) 2013-04-30
WO2003082893A8 (en) 2003-12-31
RU2004130281A (en) 2006-01-20
CN1642558A (en) 2005-07-20
CN1642558B (en) 2012-05-30
KR20100093621A (en) 2010-08-25
NZ547897A (en) 2008-02-29
ATE424211T1 (en) 2009-03-15
NZ547344A (en) 2007-11-30
TWI329016B (en) 2010-08-21
IL164161A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
WO2003082893A8 (en) Theraputic methods and uses of sapogenins and their derivatives
WO2002079221A3 (en) Sapogenin derivatives, their synthesis and use
WO2001049703A3 (en) Substituted sapogenins and their use
PL343508A1 (en) Smilagenin and anzurogenin-d and their use
GB9923076D0 (en) Sapogenin derivatives and their use
WO2003082208A8 (en) Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
CA2385410A1 (en) Sapogenin derivatives and their use in the treatment of cognitive dysfunction
WO2001079164A3 (en) N-substituted dithiocarbamates for the treatment of biological disorders
HK1040184A1 (en) Combination therapy for treating glaucoma
WO2005000208A3 (en) Combination therapy for the treatment of neoplasms
GB9923078D0 (en) Sapogenin derivatives and their use
WO2004009064A8 (en) Use of neurotoxic substances for the production of a means for the treatment of joint pain and method for application of said means
WO2004034889A3 (en) Photodynamic therapy for ocular neovascularization
WO2004105696A3 (en) Combination therapy for the treatment of neoplasms
HRP20041009A2 (en) Theraputic methods and uses of sapogenins and their derivatives
IL171384A (en) Use of slurp-1 in the preparation of medicaments for the treatment of neurological disorders
WO2005058911A3 (en) Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma
TW200833344A (en) Therapeutic methods and uses of sapogenins and their derivatives
AU2002315485A1 (en) Compositions and methods for the treatment of body weight disorders, including obesity
WO2005124563A9 (en) Compounds and kits for treating muscle disorders and methods of use thereof
BR0308788A (en) Therapeutic processes and uses of sapogenins and their derivatives
AU2003251734A1 (en) Nicergoline, mmdl and mdl for the treatment of neurodegenerative disorders of the retina and optic nerve
WO2004103985A3 (en) Derivatives of fusarochromanone as therapeutic agents
WO2004073631A3 (en) Combination therapy for the treatment of neoplasms
AU2002951831A0 (en) Underpants for the treatment of pelvic floor muscles and/or bladder

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003722713

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2477787

Country of ref document: CA

Ref document number: 1-2004-501326

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 535093

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 502/MUMNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020047014567

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 164161

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/009321

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2003580357

Country of ref document: JP

Ref document number: 2003229877

Country of ref document: AU

Ref document number: 20038071886

Country of ref document: CN

Ref document number: 372941

Country of ref document: PL

ENP Entry into the national phase

Ref document number: 2004130281

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: P20041009A

Country of ref document: HR

WWP Wipo information: published in national office

Ref document number: 1020047014567

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003722713

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10507000

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 12007501847

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 196300

Country of ref document: IL